vTv Therapeutics Inc (VTVT) Actualités

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

HIGH POINT, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT PR Newswire WESTON, Fla...

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Recently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D...

Form 3 - Initial statement of beneficial ownership of securities

Form D - Notice of Exempt Offering of Securities

Form SC 13D - General statement of acquisition of beneficial ownership

Form 8-K - Current report

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

HIGH POINT, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage...

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

HIGH POINT, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage...

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report